



# Abstract Submission Guidelines

## Important Dates

Abstract submission site opens	Tuesday, November 12, 2024
Abstract submission deadline	Tuesday, January 14, 2025
Abstract decision date	Friday, February 7, 2025
Abstract withdrawal deadline	Friday, February 14, 2025
Late-breaking abstract submission opens	Wednesday, January 15, 2025
Late-breaking abstract submission deadline	Tuesday, February 11, 2025
Late-breaking abstract decision date	Tuesday, February 18, 2025
JSCAI simultaneous publication submission deadline	Monday, March 3, 2025
Abstracts available on the SCAI meeting app	Thursday, April 17, 2025
Abstracts (except late breakers) available at JSCAI.org	Thursday, May 1, 2025

## Formatting

1. **Character limit:** Abstracts are limited to 1,900 characters, not including spaces (approximately 300-400 words). Abstracts must be submitted in American English.
2. **Format:** Abstracts must contain the following 4 sections: Background, Methods, Results, and Conclusions.
3. **Authorship:** There is no limit on the number of authors; however, all authors should satisfy the [ICMJE authorship criteria](#). Group names are not permitted, SCAI only allows individual names.
4. **Figures/Tables:** A maximum of 3 images can be included in each abstract. The following file formats are accepted: JPG/JPEG, PNG, and GIF. Each image counts as 500 characters toward the character limit.

## Policies

1. By submitting an abstract to SCAI Scientific Sessions, authors attest that the submission is exclusive to SCAI, has not been previously presented or published, and is not under consideration for any other conference.
2. Investigators should not submit multiple versions of the same research; submissions that appear to be duplicate versions of a single study will be rejected.
3. Abstracts describing work posted to a preprint server prior to submission to SCAI will be considered. If accepted, SCAI encourages making the full manuscript available and accessible on your poster or during the presentation via QR code or link.
4. Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should use these technologies only to improve readability and language. The technology should be applied with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Any use of AI must be disclosed by selecting a checkbox in the abstract submission system. If "yes" is selected, the following statement will appear in the online abstract, meeting app, and with the published abstract in JSCAI: "During the preparation of this work, the author(s) used generative AI or AI-

assisted technology. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication." This declaration is not required for basic tools used for grammar, spelling, or reference checks.

5. The SCAI Program Committee endorses the position of the American Association for the Advancement for Science ([AAAS](#)) in requiring assurances of the responsible use of animals in research as well as the ethical principles outlined in the [World Medical Association \(WMA\) Declaration of Helsinki](#) for human medical research. All submissions for consideration must follow these guidelines.
6. Authors must disclose if the research is commercially supported when submitting the abstract. This information will also be disclosed upon publication of the abstract. Additionally, each presenting author must comply with the SCAI Disclosure Policy and provide the nature of the relationship and the associated commercial entity. All presenters at SCAI Scientific Sessions must include a slide at the beginning of their presentation or text on their poster indicating disclosure information, if applicable, or stating that they have nothing to disclose.
7. Case studies will NOT be accepted or considered for abstract presentations at SCAI Scientific Sessions. Please visit the SCAI Case Submission site to submit your case report.
8. Abstract submissions must fit into one of the following categories:
  - a. Acute Coronary Syndromes & MI
  - b. Adult Congenital
  - c. Aortic Valve Interventions
  - d. Cardio-Oncology
  - e. Cardiogenic Shock
  - f. Complex PCI & Restenosis (Excluding Left Main & Multi-Vessel Intervention)
  - g. Imaging: CT, MR, and Non-Invasive Imaging
  - h. Intervention for Stable Ischemic Heart Disease
  - i. Interventional Heart Failure (Excluding Cardiogenic Shock) and Post-Transplant Care
  - j. Interventions for Afib
  - k. Intravascular Imaging (IVUS / OCT / NIR / Other) and Physiology (FFR / iFR / MR / Other)
  - l. Left Main & Multi-Vessel Intervention
  - m. Mechanical Circulatory Support (MCS)
  - n. Miscellaneous
  - o. Other Endovascular Interventions (Including AAA, Carotid, DVT, Renal Denervation and Venous Disease)
  - p. PAD & CLI
  - q. Pediatric
  - r. Pharmacotherapy
  - s. Pulmonary Artery Interventions (Including PE & PH)
  - t. Quality Improvement
  - u. Structural Heart Disease (Excluding Valvular Interventions)
  - v. Thrombectomy and Vulnerable Plaque
  - w. Valve Interventions (Excluding Aortic Valve-Interventions)
  - x. Vascular Access and Arterial Closure Devices

## **Submission, Revision, and Withdrawal**

1. All abstract submissions must be completed by the abstract submission deadline.
2. Once an abstract is submitted, SCAI will communicate only with the designated presenting author.
3. All abstract revisions must be completed by the abstract submission deadline. Revisions will only be accepted by the presenting author. This includes changes to author names, author order, author affiliation, and the addition or deletion of authors. SCAI is not responsible for work that is not submitted by the abstract submission deadline.

4. Authors should proofread abstracts carefully to avoid errors. All abstract information, including text, title, and author names, will be published online as submitted aside from minor edits to comply with journal formatting. No edits are permitted after the abstract submission deadline on.
5. Abstracts may be withdrawn by the abstract withdrawal deadline.
6. Requests to withdraw an abstract must be submitted in writing to [abstracts@scai.org](mailto:abstracts@scai.org) by the presenting author by the abstract withdrawal deadline

## Author Consent and Copyright

1. In submitting an abstract or late-breaking clinical science, the submitter, acting on behalf of all co-authors, certifies and agrees to the following:
  - a. They have read and agreed to the SCAI abstract policies and deadlines.
  - b. If the abstract is accepted, they transfer to SCAI the copyright and all other rights in the material. However, co-authors retain:
    - i. All propriety rights other than copyright, such as patent rights.
    - ii. The right to use all of part in future works.
  - c. SCAI, and its official journal, JSCAI, reserve the rights of reproduction, distribution, display and derivatives in both print and digital format. Co-authors reserve all proprietary rights other than copyright, such as patent rights and the right to use all or part of the application in future works of their own.
  - d. Consent to SCAI promoting abstracts, late-breaking clinical science, research, and presentations to online, print, and broadcast media on behalf of Scientific Sessions.

## Decisions and Presentation

1. Abstract notifications will be sent to the presenting author by the abstract decision date.
2. Accepted abstracts (excluding late-breakers) will be published in a supplement to JSCAI. All abstracts, including late breakers, will be accessible on the meeting app
3. Information about abstract format, presentation date/time, and presentation templates will be posted on [www.scai.org](http://www.scai.org).

## Simultaneous Publications

1. Accepted abstracts, excluding late-breaking clinical science, will be published in a supplement of JSCAI.
2. SCAI encourages all authors of accepted abstracts and late-breaking clinical science to submit full manuscripts for simultaneous publication in JSCAI. For more information, go to [www.jscai.org](http://www.jscai.org) or contact [jscai@yale.edu](mailto:jscai@yale.edu).

## Content Embargo

1. All authors, presenters, company sponsors, attendees, journalists, and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies:
  - a. Scientific study results presented during Scientific Sessions must not be released publicly prior to the embargo date and time.
  - b. If the media contacts authors directly, authors, presenters, and/or company sponsors must first seek SCAI approval for information to be shared with the understanding that it is under embargo. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters, and/or company sponsors. SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., Securities and Exchange Commission requirements) must be met or in the case of a public health concern.

- c. The only exception to the above-mentioned embargo rules are closed investigator meetings for participants in the trial. The SCAI Program Committee may ask you to supply investigator meeting date/time/location information if your submission is accepted.

2. Embargo Dates and Times:

- a. **SCAI Press Program:** Abstracts included in the SCAI Press Program are embargoed from the time of submission until conclusion of the press conference in which the research is presented or until conclusion of the presentation at SCAI Scientific Sessions, whichever comes first. Authors will be notified directly if their study has been selected for the Press Program, and the specific embargo details for their study will be provided.
- b. **Abstract Availability:** Embargoed text of abstracts not in the Press Program will be made available online through SCAI's meeting website platform and app two weeks prior to the start of Scientific Sessions. **Note:** The abstract embargo still applies; however, abstract text is made available to attendees to assist in creating their itineraries for the meeting.
- c. **Oral Presentations:** Abstracts selected for oral presentation are embargoed from the time of submission until the start of their session at SCAI Scientific Sessions.
- d. **Poster Presentations:** Abstracts selected for poster presentation are embargoed from the time of submission until the start of SCAI Scientific Sessions.
- e. **Late-Breaking Abstracts:** Accepted late-breaking abstracts are embargoed until the start of the session presentation.
- f. For more information on abstract embargoes, please contact [media@scai.org](mailto:media@scai.org).